Cardiac Rhythm Management Market Analysis, Size, Trends | United States | 2025-2032 | MedSuite | Includes: Implantable Cardioverter Defibrillators, Cardiac Resynchronization Therapy Devices, and 7 more

Product Description

The United States Cardiac Rhythm Management, EP and cardiac ablation market was valued at just over $15 billion in 2025. This is expected to increase over the forecast period at a CAGR of 8.2% to exceed $26 billion.

The full report suite on the U.S. market for cardiac rhythm management (CRM), electrophysiology (EP) and cardiac ablation includes detailed analysis of the implantable cardioverter defibrillator (ICD) market, pacemaker and leadless pacemaker segments, cardiac resynchronization therapy (CRT) devices, cardiac leads, implantable loop recorders (ILRs), external defibrillators (automated external defibrillators (AEDs) and manual external defibrillators (MEDs)), EP lab systems, diagnostic EP catheters and cardiac ablation catheters. Each section includes market size, growth forecasts, pricing trends, replacement cycles, technology adoption patterns and competitive dynamics across the forecast period through 2032.

Data Types Included

• Unit Sales, Average Selling Prices, Market Size & Growth Trends
• Procedure Numbers
• Market Drivers & Limiters
• Market Forecasts Until 2032, and Historical Data to 2022
• Recent Mergers & Acquisitions
• Company Profiles and Product Portfolios
• Leading Competitors

U.S. Cardiac Rhythm Management Market Trends

A major driver of the U.S. CRM and EP market is the increasing prevalence of atrial fibrillation (AF) and overall cardiac arrhythmias. An aging population, higher rates of hypertension, obesity and diabetes and the expansion of long-term cardiac monitoring are increasing diagnosis rates nationwide. As AF-related ablation volumes grow, hospitals are investing more heavily in diagnostic EP catheters, 3D mapping systems and next-generation ablation technologies, including cryoablation, pulsed-field ablation (PFA) and high-definition mapping. This shift toward interventional treatment continues to stimulate growth in EP lab equipment, diagnostic technologies and ablation devices.

U.S. Cardiac Rhythm Management Market Share Insights

• Boston Scientific was the overall share leader in the combined U.S. market for CRM, EP and ablation devices in 2025. The company’s position is driven by strong momentum in the fastest–growing EP and ablation segments. Although Boston Scientific is not the top competitor in traditional pacemakers, ICDs or CRT devices, it holds a dominant position in several high–growth categories that significantly influence the total market. The FARAPULSE PFA platform has been a major driver of adoption following recent U.S. approvals and physician preference has rapidly accelerated market penetration. Earlier acquisitions, such as Cameron Health’s subcutaneous ICD business and Bard EP’s diagnostic portfolio, continue to support strong coverage across therapy and diagnostic segments. More recent acquisitions in advanced mapping and intravascular energy technologies have pushed the company into a period of sustained double–digit expansion in multiple segments. Boston Scientific now operates as one of the most influential companies in arrhythmia management across the United States.
• Medtronic was the second–largest competitor in the total U.S. market for CRM, EP and ablation devices in 2025. The company maintains leading positions in pacemakers, ICDs and CRT systems. Medtronic benefits from exceptionally strong customer loyalty, a large national service network and deep penetration in hospitals and EP labs. The company leads the market in magnetic resonance imaging compatible pacing and defibrillation systems. Medtronic also retains a leadership role in cryoballoon ablation with its Arctic Front Advance Pro system, which now incorporates software designed to assist with lesion assessment and procedural efficiency. The Micra family of leadless pacemakers, including the most recent Micra AV2 and VR2 models, continues to drive rapid growth in the minimally invasive pacing category. Although Medtronic plays a smaller role in mapping and radiofrequency ablation than Boston Scientific or Biosense Webster, its strength in core CRM systems secures a substantial total market share.
• Johnson and Johnson, operating through Biosense Webster, is the leading EP company in the U.S. in 2025. The company holds dominant shares in 3D mapping systems, diagnostic EP catheters and radiofrequency ablation catheters. The CARTO 3D mapping system and the THERMOCOOL SMARTTOUCH SF ablation catheter portfolio remain essential components of AF workflows in most EP labs across the country. Biosense Webster is actively developing a PFA platform called VARIPULSE in order to compete in the fastest–expanding energy modality in the market. The company is supported by a continuous stream of clinical evidence, training programs and integration with broader Johnson and Johnson MedTech divisions. Although it has limited involvement in pacemakers, ICDs and CRT devices, Biosense Webster’s unmatched EP leadership secures a strong overall competitive position across the arrhythmia care landscape.

U.S. Cardiac Rhythm Management Market Segmentation Summary

• Pacemaker Market – Further Segmented Into:
  • Device Type: Single-Chamber Pacemaker, and Dual-Chamber Pacemaker.
• Implantable Cardioverter Defibrillator Market – Further Segmented Into:
  • Device Type: Single-Chamber ICD, Dual-Chamber ICD, S-ICD, and EV-ICD.
• Cardiac Resynchronization Therapy Device Market – Further Segmented Into:
  • Device Type: CRT-P, and CRT-D.
• Cardiac Lead Market – Further Segmented Into:
  • Device Type: Pacing Lead, Defibrillation Lead, and LV Lead.
• Insertable Cardiac Monitor Market
• Electrophysiology Lab System Market – Further Segmented Into:
  • Device Type: 3D Mapping System, EP Recording System, Rf Ablation Generators, and Remote Steering Systems.
• Diagnostic Electrophysiology Catheter Market – Further Segmented Into:
  • Device Type: Conventional EP Catheter, Advanced EP Catheter, and ICE Catheter.
• Cardiac Ablation Catheter Market – Further Segmented Into:
  • Device Type: RF Ablation Catheter, Cryoablation Catheter, and Pulse Field Ablation Catheter.
• External Defibrillator Market – Further Segmented Into:
  • Device Type: Automated External Defibrillator, and Manual External Defibrillator.

Research Scope Summary